The information on this website is intended to provide scientific information about Alkermes products and areas of therapeutic interest. Information may include data on investigational uses of approved or unapproved drugs for which safety and effectiveness have not been established. There is no guarantee that such uses will receive health authority approval and Alkermes does not recommend or suggest use of its medicines in a manner inconsistent with approved labeling.

This section includes selected Alkermes abstracts, posters or oral presentations, which have been accepted for congress presentations in the last 2 years. The content contained in this section is subject to congress copyright permissions.

ASCP 2026
American Society of Clinical Psychopharmacology
May 26th – 29th 2026, Miami, FL
Explore materials from this congress
PLEASE NOTE: Materials will be available on a rolling basis after individual embargoes are lifted. Audio abstracts are generated using text-to-speech software and contain an audio version of the abstract that was submitted and accepted as part of the official conference materials.
Schizophrenia
POSTER
Inpatient Initiation of the Long-Acting Injectable Antipsychotic Aripiprazole Lauroxil for the Treatment of Acute Exacerbations of Schizophrenia
AUTHOR(S)

Peter J. Weiden, MD,1 Jelena Kunovac, MD, MS,2-4 Shifang Liu, PhD,5 Daniel J. Kim, PhD,5 James A. McGrory, PhD5

View poster
Schizophrenia
Sleep-wake disorders
POSTER
Orexin 2 Receptor Agonists as a Potential Therapeutic Approach to the Treatment of Sleep-Wake Disturbance, Fatigue, and Cognitive Deficit in Neuropsychiatric Disease
AUTHOR(S)

David T. Plante,1 Andrew J. Cutler,2,3 Julie Brooks,4 Ishani Landry,4 Bhaskar Rege,4 Julie Himes,4 Craig Hopkinson,4 and Emmanuel Mignot5

View poster
Sleep-wake disorders
Schizophrenia
POSTER
Real-World Persistence on Olanzapine/Samidorphan Versus Other Oral Second-Generation Antipsychotics in Patients With Schizophrenia
AUTHOR(S)

Andrew J. Cutler, MD,1,2 Christoph U. Correll, MD,3-7 Rakesh Jain, MD, MPH,8 Craig Chepke, MD,9,10 Hara E. Oyedeji, DNP, PMHNP-BC,11 Alejandro G. Hughes, MPH,12 Noah S. Webb, PhD,12 Michael J. Doane, PhD,13 Hemangi R. Panchmatia, MSc13

View poster
Schizophrenia
Bipolar Disorder
Schizophrenia
POSTER
Real-World Comparison of Olanzapine/Samidorphan vs Olanzapine: An Assessment of Treatment Patterns and Acute Care Events Among Patients With Schizophrenia or Bipolar I Disorder
AUTHOR(S)

Hemangi R. Panchmatia, MSc,1 Rakesh Jain, MD, MPH,2 Alejandro G. Hughes, MPH,3 Michael J. Doane, PhD,1 Craig Chepke, MD,4,5 Andrew J. Cutler, MD6,7

View poster
Bipolar Disorder
Schizophrenia
Schizophrenia
POSTER
Safety and Efficacy of Aripiprazole Lauroxil in an Outpatient Setting After Initiation During Hospitalization for an Acute Exacerbation of Schizophrenia
AUTHOR(S)

Peter J. Weiden, MD,1 Jelena Kunovac, MD, MS,2-4 Shifang Liu, PhD,5 Daniel J. Kim, PhD,5 James A. McGrory, PhD5

View poster
Schizophrenia
Bipolar Disorder
Schizophrenia
POSTER
Real-World Impact of Olanzapine and Samidorphan on Rates of Relapse Among Young Adults With Schizophrenia or Bipolar I Disorder
AUTHOR(S)

Andrew J. Cutler, MD,1,2 Hemangi R. Panchmatia, MSc,3 Alejandro G. Hughes, MPH,4 Michael J. Doane, PhD,3 Hara E. Oyedeji, DNP, PMHNP-BC,5 Rakesh Jain, MD6

View poster
Bipolar Disorder
Schizophrenia
Bipolar Disorder
Schizophrenia
POSTER
Olanzapine and Samidorphan in Adults With Schizophrenia or Bipolar I Disorder: Updated Review of Clinical Data
AUTHOR(S)

Leslie Citrome, MD, MPH,1 Christoph U. Correll, MD,2-6 Roger S. McIntyre, MD,7 Mark S. Todtenkopf, PhD,8 Christina Arevalo, MS,8 James A. McGrory, PhD,8 David McDonnell, MD9

View poster
Bipolar Disorder
Schizophrenia
Sleep-wake disorders
POSTER
Safety and Efficacy Results From the Phase 2 Vibrance-1 Study of the Orexin 2 Receptor Agonist Alixorexton in Patients With Narcolepsy Type 1
AUTHOR(S)

Giuseppe Plazzi,1,2 Ronald R. Grunstein,3,4 Emmanuel Mignot,5 Gert J. Lammers,6,7 David T. Plante,8 Erik Buntinx,9 Rafael del Río Víllegas,10,11 Hailu Chen,12 Alexandra Lovett,12 Craig Hopkinson,12 Bhaskar Rege,12 Julie Himes,12 Yves Dauvilliers13

View poster
Sleep-wake disorders
Sleep-wake disorders
POSTER
Real-World Experience and Impact of Fatigue in Narcolepsy and Idiopathic Hypersomnia From the ASPIRE Survey Study
AUTHOR(S)

Michael J. Doane,1 Jane Lazar Tucker,2 Kristen McCausland,2 Claire Wylds-Wright,3,4 Lindsay Jesteadt3,4

View poster
Sleep-wake disorders
Sleep-wake disorders
POSTER
Effects of Alixorexton on Patient-Reported Disease Severity, Cognitive Functioning, and Fatigue in Patients With Narcolepsy Type 1: Results From the Phase 2 Vibrance-1 Study
AUTHOR(S)

Yves Dauvilliers,1 Ronald R. Grunstein,2,3 Emmanuel Mignot,4 Gert J. Lammers,5,6 David T. Plante,7 Erik Buntinx,8 Rafael del Río Víllegas,9,10 Hailu Chen,11 Craig Hopkinson,11 Bhaskar Rege,11 Julie Himes,11 Michael J. Doane,11 Giuseppe Plazzi12,13

View poster
Sleep-wake disorders
Sleep-wake disorders
POSTER
Real-World Experience and Impact of Cognitive Impairment in Narcolepsy and Idiopathic Hypersomnia From the ASPIRE Survey Study
AUTHOR(S)

Michael J. Doane,1 Jane Lazar Tucker,2 Kristen McCausland,2 Lindsay Jesteadt,3,4 Claire Wylds-Wright3,4

View poster
Sleep-wake disorders